Literature DB >> 22435528

Serum markers of apoptosis in the early period of heart transplantation.

Ignacio J Sánchez-Lázaro1, Luis Almenar-Bonet, Ana Romero-Pelechano, Manuel Portoles-Sanz, Luis Martínez-Dolz, Esther Roselló-Lleti, José Ramón González-Juanatey, Miguel Rivera-Otero, Antonio Salvador-Sanz.   

Abstract

CONTEXT AND
OBJECTIVE: To assess the relationship between levels of serum markers of apoptosis and rejection grades in heart transplant (HTx).
MATERIALS AND METHODS: A prospective study was conducted in 91 HTx. We correlated apoptosis markers and biopsy samples. The apoptosis markers were: TRAIL, TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, sFas, sTNF-R1 and sTNF-R2.
RESULTS: The only significant correlation with rejection grade was sFas (r=0.329; p=0.005). Cyclosporine showed a proapoptotic effect (sTNF-R1 0.02 and sTNF-R2 0.02) and everolimus an antiapoptotic effect (sTNF-R1 r= -0.523; p=0.0001 and sTNF-R2 r= -0.405; p=0.0001).
CONCLUSIONS: The utility of specific apoptosis markers in peripheral blood for diagnosis of acute cellular rejection is low. Everolimus may have an anti-apoptotic effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22435528     DOI: 10.3109/1354750X.2012.664168

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  3 in total

1.  The changes of vaccinia related kinase 1 in grafted heart after rat heart transplantation.

Authors:  Shiguo Qian; Xuechao Yang; Kunpeng Wu; Qiangsheng Lv; Yuanyuan Zhang; Jiahong Dai; Cheng Chen; Jiahai Shi
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

2.  POLE2 knockdown reduce tumorigenesis in esophageal squamous cells.

Authors:  Yongjun Zhu; Gang Chen; Yang Song; Zhiming Chen; Xiaofeng Chen
Journal:  Cancer Cell Int       Date:  2020-08-11       Impact factor: 5.722

3.  Targeting POLE2 Creates a Novel Vulnerability in Renal Cell Carcinoma via Modulating Stanniocalcin 1.

Authors:  Chuanjie Zhang; Yan Shen; Lili Gao; Xiaojing Wang; Da Huang; Xin Xie; Danfeng Xu; Hongchao He
Journal:  Front Cell Dev Biol       Date:  2021-02-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.